(Q31030179)

28 June 2017

1 reference

title

The measurement and clinical relevance of brain atrophy in multiple sclerosis (English)

1 reference

28 June 2017

0 references

Robert A Bermel

1

1 reference

PubMed ID

16426992

28 June 2017

Rohit Bakshi

series ordinal

2

1 reference

28 June 2017

1 February 2006

1 reference

28 June 2017

1 reference

28 June 2017

5

1 reference

28 June 2017

2

1 reference

28 June 2017

158-170

1 reference

Imaging the optic nerve in multiple sclerosis.

28 June 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970349-0

7 January 2021

Inflammatory central nervous system demyelination: correlation of magnetic resonance imaging findings with lesion pathology.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970349-0

7 January 2021

Imaging of multiple sclerosis: role in neurotherapeutics

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970349-0

7 January 2021

A longitudinal MRI study of histopathologically defined hypointense multiple sclerosis lesions

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970349-0

7 January 2021

Histopathologic correlate of hypointense lesions on T1-weighted spin-echo MRI in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970349-0

7 January 2021

The longitudinal relation between brain lesion load and atrophy in multiple sclerosis: a 14 year follow up study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970349-0

7 January 2021

Early development of multiple sclerosis is associated with progressive grey matter atrophy in patients presenting with clinically isolated syndromes

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970349-0

7 January 2021

Use of the brain parenchymal fraction to measure whole brain atrophy in relapsing-remitting MS. Multiple Sclerosis Collaborative Research Group

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970349-0

7 January 2021

Prediction of longitudinal brain atrophy in multiple sclerosis by gray matter magnetic resonance imaging T2 hypointensity

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970349-0

7 January 2021

Brain atrophy in relapsing-remitting multiple sclerosis: fractional volumetric analysis of gray matter and white matter

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970349-0

7 January 2021

Brain atrophy in clinically early relapsing-remitting multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970349-0

7 January 2021

Brain tissue volume changes in relapsing-remitting multiple sclerosis: correlation with lesion load.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970349-0

7 January 2021

Brain atrophy and lesion load in a large population of patients with multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970349-0

7 January 2021

The relationship between whole brain volume and disability in multiple sclerosis: a comparison of normalized gray vs. white matter with misclassification correction.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970349-0

7 January 2021

Selective caudate atrophy in multiple sclerosis: a 3D MRI parcellation study.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970349-0

7 January 2021

Is gadolinium enhancement predictive of the development of brain atrophy in multiple sclerosis? A review of the literature

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970349-0

7 January 2021

Enhancing magnetic resonance imaging lesions and cerebral atrophy in patients with relapsing multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970349-0

7 January 2021

Short-term brain volume change in relapsing-remitting multiple sclerosis: effect of glatiramer acetate and implications

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970349-0

7 January 2021

A longitudinal study of brain atrophy in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG).

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970349-0

7 January 2021

Short-term brain atrophy changes in relapsing–remitting multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970349-0

7 January 2021

The effect of gadolinium-enhancing lesions on whole brain atrophy in relapsing-remitting MS

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970349-0

7 January 2021

The effect of interferon beta-1b treatment on MRI measures of cerebral atrophy in secondary progressive multiple sclerosis. European Study Group on Interferon beta-1b in secondary progressive multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970349-0

7 January 2021

Quantitative MRI in patients with secondary progressive MS treated with monoclonal antibody Campath 1H.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970349-0

7 January 2021

Brain atrophy in relapsing-remitting multiple sclerosis: relationship with 'black holes', disease duration and clinical disability.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970349-0

7 January 2021

A semiautomated measure of whole-brain atrophy in multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970349-0

7 January 2021

Bicaudate ratio as a magnetic resonance imaging marker of brain atrophy in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970349-0

7 January 2021

Axonal transection in the lesions of multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970349-0

7 January 2021

A Wallerian degeneration pattern in patients at risk for MS.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970349-0

7 January 2021

Neuronal cell injury precedes brain atrophy in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970349-0

7 January 2021

MR correlates of cerebral atrophy in patients with multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970349-0

7 January 2021

Accelerated evolution of brain atrophy and "black holes" in MS patients with APOE-epsilon 4.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970349-0

7 January 2021

Gray matter T2 hypointensity is related to plaques and atrophy in the brains of multiple sclerosis patients.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970349-0

7 January 2021

T2 hypointensity in the deep gray matter of patients with multiple sclerosis: a quantitative magnetic resonance imaging study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970349-0

7 January 2021

Regional brain atrophy is associated with physical disability in multiple sclerosis: semiquantitative magnetic resonance imaging and relationship to clinical findings.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970349-0

7 January 2021

Evidence of early cortical atrophy in MS: relevance to white matter changes and disability.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970349-0

7 January 2021

Gray and white matter volume changes in early RRMS: a 2-year longitudinal study.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970349-0

7 January 2021

Grey and white matter atrophy in early clinical stages of primary progressive multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970349-0

7 January 2021

Gray and white matter brain atrophy and neuropsychological impairment in multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970349-0

7 January 2021

Focal thinning of the cerebral cortex in multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970349-0

7 January 2021

Progressive grey matter atrophy in clinically early relapsing-remitting multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970349-0

7 January 2021

Transected neurites, apoptotic neurons, and reduced inflammation in cortical multiple sclerosis lesions.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970349-0

7 January 2021

Thalamic neurodegeneration in multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970349-0

7 January 2021

Serial MRI in multiple sclerosis: a prospective pilot study of lesion load, whole brain volume and thalamic atrophy.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970349-0

7 January 2021

High-resolution fluorodeoxyglucose positron emission tomography shows both global and regional cerebral hypometabolism in multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970349-0

7 January 2021

Functional magnetic resonance imaging correlates of fatigue in multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970349-0

7 January 2021

Indirect evidence for early widespread gray matter involvement in relapsing-remitting multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970349-0

7 January 2021

Prediction of neuropsychological impairment in multiple sclerosis: comparison of conventional magnetic resonance imaging measures of atrophy and lesion burden.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970349-0

7 January 2021

Intercaudate nucleus ratio as a linear measure of brain atrophy in multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970349-0

7 January 2021

The correlation between ventricular diameter measured by transcranial sonography and clinical disability and cognitive dysfunction in patients with multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970349-0

7 January 2021

Determination of ventricular diameters in multiple sclerosis patients with transcranial sonography (TCS)--a two year follow-up study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970349-0

7 January 2021

Measurement error of two different techniques for brain atrophy assessment in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970349-0

7 January 2021

Correction for intracranial volume in analysis of whole brain atrophy in multiple sclerosis: the proportion vs. residual method.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970349-0

7 January 2021

Brain atrophy in relapsing-remitting multiple sclerosis and secondary progressive multiple sclerosis: longitudinal quantitative analysis.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970349-0

7 January 2021

Accurate, robust, and automated longitudinal and cross-sectional brain change analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970349-0

7 January 2021

MRI lesion volume heterogeneity in primary progressive MS in relation with axonal damage and brain atrophy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970349-0

7 January 2021

Serial neuropsychological assessment and magnetic resonance imaging analysis in multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970349-0

7 January 2021

Automated segmentation and measurement of global white matter lesion volume in patients with multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970349-0

7 January 2021

Progressive ventricular enlargement in patients with clinically isolated syndromes is associated with the early development of multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970349-0

7 January 2021

Sensitivity and reproducibility of a new fast 3D segmentation technique for clinical MR-based brain volumetry in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970349-0

7 January 2021

Progressive cerebral atrophy in MS: a serial study using registered, volumetric MRI

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970349-0

7 January 2021

Normalized accurate measurement of longitudinal brain change.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970349-0

7 January 2021

Voxel-based morphometry–the methods

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970349-0

7 January 2021

The reproducibility and sensitivity of brain tissue volume measurements derived from an SPM-based segmentation methodology.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970349-0

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970349-0

7 January 2021

White matter abnormalities in mobility-impaired older persons

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970349-0

7 January 2021

Reproducibility and accuracy of quantitative magnetic resonance imaging techniques of whole-brain atrophy measurement in multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970349-0

7 January 2021

The relationship between inflammation and atrophy in clinically isolated syndromes suggestive of multiple sclerosis: a monthly MRI study after triple-dose gadolinium-DTPA

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970349-0

7 January 2021

Detection of ventricular enlargement in patients at the earliest clinical stage of MS

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970349-0

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970349-0

7 January 2021

Interferon beta-1a for brain tissue loss in patients at presentation with syndromes suggestive of multiple sclerosis: a randomised, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970349-0

7 January 2021

A longitudinal study of brain atrophy and cognitive disturbances in the early phase of relapsing-remitting multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970349-0

7 January 2021

Longitudinal brain volume measurement in multiple sclerosis: rate of brain atrophy is independent of the disease subtype.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970349-0

7 January 2021

Short-term ventricular volume changes on serial MRI in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970349-0

7 January 2021

Quantitative brain volumetric analysis from patients with multiple sclerosis: a follow-up study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970349-0

7 January 2021

Role of MRI in multiple sclerosis II: brain and spinal cord atrophy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970349-0

7 January 2021

The relationship of brain and cervical cord volume to disability in clinical subtypes of multiple sclerosis: a three-dimensional MRI study.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970349-0

7 January 2021

Progressive cerebral atrophy in multiple sclerosis. A serial MRI study.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970349-0

7 January 2021

Glatiramer acetate (Copaxone) treatment in relapsing-remitting MS: quantitative MR assessment.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970349-0

7 January 2021

Cerebral atrophy and disability in relapsing-remitting and secondary progressive multiple sclerosis over four years.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970349-0

7 January 2021

MRI brain volume changes in relapsing-remitting multiple sclerosis patients treated with interferon beta-1a.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970349-0

7 January 2021

Whole brain volume changes in patients with progressive MS treated with cladribine.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970349-0

7 January 2021

One year follow up study of primary and transitional progressive multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970349-0

7 January 2021

Primary progressive multiple sclerosis: a 5-year clinical and MR study.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970349-0

7 January 2021

Interferon beta-1a in primary progressive MS: an exploratory, randomized, controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970349-0

7 January 2021

Volumes of brain atrophy and plaques correlated with neurological disability in secondary progressive multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970349-0

7 January 2021

Eight-year follow-up study of brain atrophy in patients with MS.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970349-0

7 January 2021

Correlating brain atrophy with cognitive dysfunction, mood disturbances, and personality disorder in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970349-0

7 January 2021

Quality of life and its relationship to brain lesions and atrophy on magnetic resonance images in 60 patients with multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970349-0

7 January 2021

Brain MRI lesions and atrophy are related to depression in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970349-0

7 January 2021

Cognitive impairment in early-onset multiple sclerosis. Pattern, predictors, and impact on everyday life in a 4-year follow-up

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970349-0

7 January 2021

Cognitive dysfunction in multiple sclerosis. I. Frequency, patterns, and prediction

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970349-0

7 January 2021

The progress of cognitive decline in multiple sclerosis. A controlled 3-year follow-up.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970349-0

7 January 2021

Cognitive disturbances in patients with relapsing remitting multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970349-0

7 January 2021

Multiple memory deficits in patients with multiple sclerosis. Exploring the working memory system.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970349-0

7 January 2021

Deficient learning and memory in early and middle phases of multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970349-0

7 January 2021

Speed of information processing as a key deficit in multiple sclerosis: implications for rehabilitation

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970349-0

7 January 2021

Chronic progressive multiple sclerosis. Relationship between cerebral ventricular size and neuropsychological impairment

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970349-0

7 January 2021

Magnetic resonance imaging correlates of neuropsychological impairment in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970349-0

7 January 2021

A longitudinal study of callosal atrophy and interhemispheric dysfunction in relapsing-remitting multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970349-0

7 January 2021

Depressive symptoms and MRI changes in multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970349-0

7 January 2021

Structural brain abnormalities in multiple sclerosis patients with major depression

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970349-0

7 January 2021

Cognitive performance and MR markers of cerebral injury in cognitively impaired MS patients

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970349-0

7 January 2021

Has your patient's multiple sclerosis lesion burden or brain atrophy actually changed?

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970349-0

7 January 2021

Whole-brain atrophy in multiple sclerosis measured by two segmentation processes from various MRI sequences.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970349-0

7 January 2021

Apparent Cerebral Atrophy in Patients on Treatment with Steroids

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970349-0

7 January 2021

Cerebral volume changes in multiple sclerosis patients treated with high-dose intravenous methylprednisolone

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970349-0

7 January 2021

Methylprednisolone effect on brain volume and enhancing lesions in MS before and during IFNbeta-1b

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970349-0

7 January 2021

Brain atrophy and magnetization transfer ratio following methylprednisolone in multiple sclerosis: short-term changes and long-term implications

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970349-0

7 January 2021

Effects of IV methylprednisolone on brain atrophy in relapsing-remitting MS.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970349-0

7 January 2021

Brain atrophy in relapsing multiple sclerosis: relationship to relapses, EDSS, and treatment with interferon beta-1a

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970349-0

7 January 2021

Measurement of brain and spinal cord atrophy by magnetic resonance imaging as a tool to monitor multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970349-0

7 January 2021

Rate of brain atrophy in relapsing MS decreases during treatment with IFNbeta-1a.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970349-0

7 January 2021

Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970349-0

7 January 2021

Randomized controlled trial of interferon- beta-1a in secondary progressive MS: Clinical results

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970349-0

7 January 2021

Spinal cord atrophy and disability in multiple sclerosis over four years: application of a reproducible automated technique in monitoring disease progression in a cohort of the interferon beta-1a (Rebif) treatment trial

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970349-0

7 January 2021

Interferon-beta-1b slows progression of atrophy in RRMS: Three-year follow-up in NAb- and NAb+ patients.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970349-0

7 January 2021

Biomarkers and surrogate outcomes in neurodegenerative disease: lessons from multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970349-0

7 January 2021

Interferon beta promotes nerve growth factor secretion early in the course of multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970349-0

7 January 2021

Interferon beta in the treatment of multiple sclerosis: mechanisms of action

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970349-0

7 January 2021

10.1016/S1474-4422(06)70349-0

Identifiers

DOI

1 reference

28 June 2017

1 reference

PubMed ID

16426992